|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: U2AF1L4 |
Gene summary for U2AF1L4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | U2AF1L4 | Gene ID | 199746 |
| Gene name | U2 small nuclear RNA auxiliary factor 1 like 4 | |
| Gene Alias | U2AF1-RS3 | |
| Cytomap | 19q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | Q8WU68 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 199746 | U2AF1L4 | LZE4T | Human | Esophagus | ESCC | 3.29e-05 | 2.06e-01 | 0.0811 |
| 199746 | U2AF1L4 | LZE7T | Human | Esophagus | ESCC | 9.96e-13 | 4.14e-01 | 0.0667 |
| 199746 | U2AF1L4 | LZE8T | Human | Esophagus | ESCC | 6.43e-04 | 1.51e-01 | 0.067 |
| 199746 | U2AF1L4 | LZE20T | Human | Esophagus | ESCC | 5.54e-06 | 1.81e-01 | 0.0662 |
| 199746 | U2AF1L4 | LZE24T | Human | Esophagus | ESCC | 4.41e-09 | 2.16e-01 | 0.0596 |
| 199746 | U2AF1L4 | LZE6T | Human | Esophagus | ESCC | 4.22e-07 | 2.19e-01 | 0.0845 |
| 199746 | U2AF1L4 | P1T-E | Human | Esophagus | ESCC | 8.09e-05 | 2.79e-01 | 0.0875 |
| 199746 | U2AF1L4 | P2T-E | Human | Esophagus | ESCC | 2.03e-09 | 1.69e-01 | 0.1177 |
| 199746 | U2AF1L4 | P4T-E | Human | Esophagus | ESCC | 3.60e-03 | 9.21e-02 | 0.1323 |
| 199746 | U2AF1L4 | P5T-E | Human | Esophagus | ESCC | 4.41e-07 | 1.39e-01 | 0.1327 |
| 199746 | U2AF1L4 | P8T-E | Human | Esophagus | ESCC | 1.53e-19 | 3.16e-01 | 0.0889 |
| 199746 | U2AF1L4 | P9T-E | Human | Esophagus | ESCC | 1.61e-11 | 2.11e-01 | 0.1131 |
| 199746 | U2AF1L4 | P10T-E | Human | Esophagus | ESCC | 6.31e-48 | 6.97e-01 | 0.116 |
| 199746 | U2AF1L4 | P11T-E | Human | Esophagus | ESCC | 7.70e-12 | 4.11e-01 | 0.1426 |
| 199746 | U2AF1L4 | P12T-E | Human | Esophagus | ESCC | 4.24e-18 | 2.82e-01 | 0.1122 |
| 199746 | U2AF1L4 | P15T-E | Human | Esophagus | ESCC | 4.10e-08 | 1.92e-01 | 0.1149 |
| 199746 | U2AF1L4 | P16T-E | Human | Esophagus | ESCC | 1.94e-06 | 1.54e-01 | 0.1153 |
| 199746 | U2AF1L4 | P17T-E | Human | Esophagus | ESCC | 1.13e-06 | 2.37e-01 | 0.1278 |
| 199746 | U2AF1L4 | P20T-E | Human | Esophagus | ESCC | 4.98e-09 | 2.22e-01 | 0.1124 |
| 199746 | U2AF1L4 | P21T-E | Human | Esophagus | ESCC | 7.90e-03 | 6.37e-02 | 0.1617 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
| GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
| GO:000037519 | Oral cavity | OSCC | RNA splicing, via transesterification reactions | 225/7305 | 324/18723 | 5.20e-29 | 2.99e-26 | 225 |
| GO:000037719 | Oral cavity | OSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:000039819 | Oral cavity | OSCC | mRNA splicing, via spliceosome | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa05131310 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa0513130 | Oral cavity | OSCC | Shigellosis | 150/3704 | 247/8465 | 3.96e-08 | 3.12e-07 | 1.59e-07 | 150 |
| hsa0304016 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa05131113 | Oral cavity | OSCC | Shigellosis | 150/3704 | 247/8465 | 3.96e-08 | 3.12e-07 | 1.59e-07 | 150 |
| hsa0304017 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| U2AF1L4 | SNV | Missense_Mutation | c.184N>A | p.Val62Met | p.V62M | Q8WU68 | protein_coding | deleterious(0.02) | possibly_damaging(0.771) | TCGA-A6-4107-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5 | SD | |
| U2AF1L4 | SNV | Missense_Mutation | novel | c.537N>T | p.Trp179Cys | p.W179C | Q8WU68 | protein_coding | deleterious_low_confidence(0) | benign(0.003) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| U2AF1L4 | SNV | Missense_Mutation | rs142741890 | c.257N>A | p.Arg86Gln | p.R86Q | Q8WU68 | protein_coding | deleterious(0.04) | benign(0.161) | TCGA-CM-4746-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| U2AF1L4 | SNV | Missense_Mutation | c.341G>A | p.Cys114Tyr | p.C114Y | Q8WU68 | protein_coding | deleterious(0) | possibly_damaging(0.674) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| U2AF1L4 | SNV | Missense_Mutation | rs755077639 | c.280N>T | p.Arg94Cys | p.R94C | Q8WU68 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-CI-6623-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| U2AF1L4 | deletion | Frame_Shift_Del | c.582delN | p.Arg196GlyfsTer6 | p.R196Gfs*6 | Q8WU68 | protein_coding | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| U2AF1L4 | SNV | Missense_Mutation | novel | c.32C>T | p.Thr11Ile | p.T11I | Q8WU68 | protein_coding | deleterious(0) | possibly_damaging(0.731) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| U2AF1L4 | SNV | Missense_Mutation | novel | c.32C>T | p.Thr11Ile | p.T11I | Q8WU68 | protein_coding | deleterious(0) | possibly_damaging(0.731) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| U2AF1L4 | SNV | Missense_Mutation | novel | c.575N>T | p.Pro192Leu | p.P192L | Q8WU68 | protein_coding | deleterious_low_confidence(0) | benign(0.003) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| U2AF1L4 | SNV | Missense_Mutation | novel | c.601N>G | p.Ile201Val | p.I201V | Q8WU68 | protein_coding | deleterious_low_confidence(0) | benign(0.001) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |